Mark Y Jeng

11PUBLICATIONS
110CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 27, 2026
A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.

|Jul 14, 2026
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

|Jun 17, 2026
Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.

|Sep 24, 2025
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas.

Jessica S Ross, Rohit Thummalapalli, Kristine Lacuna

|May 15, 2025
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib.

Monica F Chen, Mark Y Jeng, Jennifer Ma

|Apr 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.

Federica Pecci, Rohit Thummalapalli, Stephanie L Alden

Pageof 2

Frequent Collaborators

4 joint publications

Helena A Yu

3 joint publications

Mark M Awad

2 joint publications

Federica Pecci

2 joint publications

Rohit Thummalapalli